The bacteria are probably there because the children have a susceptibility.
For generations, the sight of a small child struggling to breathe in an emergency room has prompted a familiar reflex: prescribe an antibiotic, address the bacteria, restore order. A large clinical trial now asks us to reconsider that reflex entirely. Researchers following 840 preschoolers through acute wheezing episodes found that azithromycin, one of medicine's most trusted antibiotics, offered no benefit whatsoever — not even in children whose airways harbored the very bacteria long suspected of driving the illness. The findings, published in The New England Journal of Medicine, suggest that what looks like a bacterial problem may be something more fundamental: a question of why certain young immune systems respond to ordinary cold viruses with such extraordinary force.
- Wheezing and asthma send roughly 30,000 American children under five to the hospital every year, making it the leading cause of pediatric hospitalization — a crisis that has long invited the comfort of a prescription.
- Despite years of skepticism in the research community, antibiotics are still given in about one in four acute wheezing cases in young children, a habit the AZ-SWED trial was specifically designed to confront.
- Even children who tested positive for potentially harmful bacteria — Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae — recovered no faster on azithromycin than on placebo, forcing a rethink of the bacterial causation theory.
- The real driver appears to be viral: 86% of study children carried respiratory viruses, and the bacteria present seem to be opportunistic passengers thriving in airways already destabilized by a dysregulated immune response.
- The trial was stopped early once interim data made the futility undeniable, and its lead researcher now calls for a categorical end to antibiotic prescribing in these cases — while warning that unnecessary use accelerates resistance and disrupts children's developing immune systems.
- The next frontier is not the bacteria at all, but the deeper question of why a subset of children mounts a severe immune response to a common cold while most others simply sniffle.
A major clinical trial has overturned a long-held assumption about severe wheezing in very young children. Researchers at the University of Arizona enrolled 840 preschoolers between 18 and 59 months old who arrived at pediatric emergency departments mid-episode. Half received azithromycin for five days; half received a placebo. Tracking breathing, coughing, appetite, and mood through parental logs, the results were unambiguous: the antibiotic made no difference at all.
The stakes are considerable. Wheezing and asthma account for more hospitalizations in American children under five than any other condition — around 30,000 admissions and 2.2 million emergency visits each year. For decades, clinicians suspected that bacteria commonly found in the airways of young wheezers — Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae — might be driving these episodes. Of the 840 children in the study, 521 tested positive for at least one of these organisms. Yet even among that group, azithromycin provided no benefit over placebo. The trial was halted early once an interim analysis confirmed the futility.
Lead researcher Dr. Fernando Martinez was direct: children presenting with severe wheezing should not receive azithromycin or any antibiotic. Yet the practice continues in roughly a quarter of such cases. The data point instead to viral infection as the primary cause — more than 86% of children in the study carried respiratory viruses, and nearly three-quarters had a common cold virus. Antibiotics cannot touch viruses. Martinez's deeper proposal is that the bacteria found in these children are opportunistic passengers, not causes: certain children, perhaps due to genetic or immunological traits, mount an exaggerated response to a cold virus, and that dysregulated environment allows bacteria to flourish as a secondary effect.
The consequences of this reframing are immediate. Unnecessary antibiotics accelerate drug resistance and disrupt the microbial development that trains a child's immune system. Published in The New England Journal of Medicine and presented at the American Thoracic Society meeting in Orlando, the findings carry the weight needed to shift clinical practice. But Martinez's team is already looking further — toward the more fundamental question of why some children's immune systems respond to ordinary cold viruses with hospitalization, while most others simply get a runny nose.
A large clinical trial has upended a long-standing assumption about what causes severe wheezing in very young children—and what doctors should do about it. Researchers at the University of Arizona College of Medicine–Tucson enrolled 840 preschoolers, ages 18 to 59 months, who arrived at eight pediatric emergency departments across the country in the grip of acute wheezing episodes. Half received azithromycin, a commonly used antibiotic, for five days. The other half received a placebo. When the researchers measured outcomes using a standard assessment tool that tracked breathing, coughing, appetite, and mood through parental daily logs, the results were unambiguous: the antibiotic made no difference. Children who took azithromycin recovered at the same rate as those who took nothing.
The finding matters because wheezing and asthma drive more hospitalizations in American children under five than any other condition—roughly 30,000 admissions annually. Another 2.2 million young children visit emergency rooms each year for wheezing episodes alone. For decades, clinicians have suspected that bacteria living in children's throats might play a role in these episodes. Three types in particular—Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae—are known to colonize the airways of children who wheeze frequently. The logic seemed sound: if bacteria are present, treat them with antibiotics. Yet the trial, called AZ-SWED, was designed to test whether this logic actually held.
Of the 840 children in the study, 521 tested positive for at least one of these potentially harmful bacteria when they arrived at the emergency department. This gave researchers a crucial opportunity: they could compare how children with bacteria responded to the antibiotic versus how children without bacteria responded. The answer was striking. Even among the children who carried these organisms, azithromycin provided no additional benefit over placebo. The antibiotic did not clear the bacteria faster, did not reduce symptoms more effectively, and did not speed recovery. The trial was halted early after an interim analysis made the futility clear.
Dr. Fernando Martinez, the lead researcher and director of the University of Arizona's Asthma and Airway Disease Research Center, drew a direct conclusion: "We can say with a high degree of certainty that children who come to the doctor's office or the emergency room with a severe wheezing episode should not be given azithromycin or any antibiotic." Yet he acknowledged that the practice persists. Clinicians still prescribe antibiotics in roughly one quarter of acute wheezing cases in young children, despite years of evidence suggesting they should not.
The real culprit, the data suggest, is viral infection. More than 86 percent of the children in the study carried one or more respiratory viruses when they presented to the emergency department. Nearly three-quarters were infected with a cold virus. When a child's immune system is already fighting a viral infection, an antibiotic cannot help—viruses do not respond to antibiotics. But the findings point to something deeper. The presence of bacteria in children with wheezing does not mean the bacteria are causing the problem. Instead, Martinez proposes, the bacteria are opportunistic passengers. Children with certain genetic or immunological traits may mount an exaggerated response to a cold virus, and that dysregulated response creates an environment where bacteria can flourish. The bacteria are a symptom of the child's vulnerability, not the root cause of the wheezing.
This reframing has immediate practical consequences. Unnecessary antibiotic use in children accelerates the development of drug-resistant bacteria—a growing public health threat. It also disrupts the normal microbial colonization that helps train a child's developing immune system. Every course of antibiotics given without clear benefit is a missed opportunity to let the body's own defenses mature. The trial results, published in The New England Journal of Medicine and presented at the American Thoracic Society meeting in Orlando, provide the kind of definitive evidence that can shift clinical practice. But Martinez and his team are not finished. They are now pursuing follow-up studies to understand why some children's immune systems respond to cold viruses with wheezing and hospitalization while most others simply develop a runny nose. That question—why this particular group of children is so vulnerable—may ultimately prove more important than the bacteria themselves.
Citações Notáveis
We can say with a high degree of certainty that children who come to the doctor's office or the emergency room with a severe wheezing episode should not be given azithromycin or any antibiotic.— Dr. Fernando Martinez, lead researcher
The fact that the children with the pathogenic bacteria didn't respond to the antibiotic—even if we eradicated the bacteria—challenges the idea that bacteria cause the wheezing.— Dr. Fernando Martinez
A Conversa do Hearth Outra perspectiva sobre a história
So the bacteria were there in more than half the children. Why didn't the antibiotic help them?
Because the bacteria weren't actually driving the wheezing. They were there because the child's immune system was already overwhelmed by a virus. The antibiotic cleared the bacteria, but the wheezing didn't improve—which tells you the bacteria weren't the problem.
But clinicians still use antibiotics a quarter of the time in these cases. What's keeping that practice alive?
Habit, partly. And the logic seems intuitive: bacteria are present, so treat them. But intuition isn't the same as evidence. This trial is the kind of large, definitive study that can finally break that pattern.
What about the children's immune systems? You mentioned they might be vulnerable in some way.
Right. Most kids get a cold and their nose runs. These children get a cold and their airways swell and they can't breathe. Something about their immune response to viruses is different—exaggerated. The bacteria just move in because the environment is already compromised.
So the next question is why some children react that way to viruses?
Exactly. That's what they're studying now. If you can understand why certain children are susceptible, you might be able to intervene earlier, before the wheezing starts—not by treating bacteria that aren't the problem, but by addressing the actual vulnerability.
And in the meantime, this trial tells doctors to stop using antibiotics for acute wheezing?
Yes. With high certainty. It's one of those rare moments where a large, well-designed study gives you a clear answer: don't do this anymore.